| 转债代码：113649 | 转债简称：丰山转债 | | | --- | --- | --- | | 证券代码：603810 | 证券简称：丰山集团 | 公告编号：2025-015 | 江苏丰山集团股份有限公司 鉴于公司 2024 年度财务报表中当期归属于上市公司股东的净利润为负值， 2024 年度公司不满足现金分红的条件。综合考虑公司的发展、资金需求及公司 分红相关规定要求的情况，为更好地维护全体股东的长远利益，公司 2024 年度 利润分配方案为：不分配利润，不进行资本公积转增股本和其他形式的分配。 本次利润分配方案尚需提交股东大会审议。 重要内容提示： 江苏丰山集团股份有限公司（以下简称"公司"）2024 年度归属于上市公 司股东的净利润为负值，公司拟不进行利润分配，也不进行资本公积转增股本和 其他形式的分配。 本次利润分配方案尚需提交公司股东大会审议。 公司不触及《上海证券交易所股票上市规则》9.8.1 条第一款第（八）项 规定的可能被实施其他风险警示的情形。 关于 2024 年度拟不进行利润分配的公告 一、2024 年度利润分配方案内容 经公证天业会计师事务所（特殊普通合伙）审计，截至 2024 ...

江苏丰山集团股份有限公司 审计报告 2024 年度 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 中国．江苏．无锡 Wuxi．Jiangsu．China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 审计报告 苏公 W[2025]A685 号 江苏丰山集团股份有限公司全体股东： 一、审计意见 我们审计了江苏丰山集团股份有限公司（以下简称丰山集团）财务报表，包括2024 年12月31日的合并及母公司资产负债表，2024年度的合并及母公司利润表、合并及母公 司现金流量表、合并及母公司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反 映了丰山集团2024年12月31日的合并及母公司财务状况以及2024年度的合并及母公司 经营成果和现金流量。 二、形成审计意见的基础 ...

江苏丰山集团股份有限公司 专项报告 2024 年 12 月 31 日 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 中国．江苏．无锡 Wuxi．Jiangsu．China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 2024 年度营业收入扣除情况的专项核查意见 苏公W[2025]E1291号 江苏丰山集团股份有限公司全体股东： 我们接受委托，审计了江苏丰山集团股份有限公司（以下简称丰山集团）财务 报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母 公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及相关 财务报表附注，并于 2025 年 4 月 28 日出具了苏公 W[2025]A685 号无保留意见审计 报告。在此基础上，我们核查了后附的丰山集团管理层编制的 ...

华泰联合证券有限责任公司 关于江苏丰山集团股份有限公司 2025 年度使用闲置募集资金和闲置自有资金 在非关联方机构进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为江苏丰山集团股份有限公司（以下简称"丰山集团"或"公司"）2018 年首次 公开发行股票和 2022 年公开发行可转换公司债券的保荐人，根据《证券发行上 市保荐业务管理办法》《上海证券交易所股票上市规则（2023 年 2 月修订）》 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所股票上市规则》等有关规定，对丰山集团 2025 年度使用闲置募集 资金和闲置自有资金在非关联方机构进行现金管理的事项进行了核查，核查意见 如下： 一、募集资金基本情况 公司经中国证券监督管理委员会《关于核准江苏丰山集团股份有限公司公开 发行可转换公司债券的批复》（证监许可[2022]961 号）核准，向社会公开发行 面值总额 50,000 万元可转换公司债券，募集资金总额 50,000 万元，扣除保荐、 承销费及其他费用 1,021.13 万元，实际募集资金净额 48,978.87 万元 ...

江苏丰山集团股份有限公司 内部控制审计报告 2024 年 12 月 31 日 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 中国．江苏．无锡 Wuxi．Jiangsu．China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 内部控制审计报告 苏公 W[2025]E1288 号 江苏丰山集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们 审计了江苏丰山集团股份有限公司（以下简称"丰山集团"）2024年12月31日的财 务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控 制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是丰山集团 董事会的责任。 三、内部控制的固有局限性 内部控制具有固有局限性，存 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1000 | -0.0700 | 242.86 | 0.0600 | | 每股净资产（元） | 9.11 | 8.98 | 1.45 | 9.47 | | 每股公积金(元) | 4.12 | 4.12 | 0 | 3.95 | | 每股未分配利润(元) | 3.37 | 3.44 | -2.03 | 3.94 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.22 | 2.63 | 22.43 | 3.96 | | 净利润(亿元) | 0.16 | -0.11 | 245.45 | 0.1 | | 净资产收益率(%) | 1.03 | -0.70 | 247.14 | 0.64 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 8912.01万股，累计占流通股比： 53.92%，较 ...

Financial Performance - The company's revenue for the first quarter reached ¥322,200,052.44, representing a year-on-year increase of 22.60% compared to ¥262,803,224.93[4] - Net profit attributable to shareholders was ¥16,375,863.17, a significant turnaround from a loss of ¥10,909,451.92 in the same period last year, marking a 250.11% increase[4] - The basic earnings per share increased to ¥0.10 from a loss of ¥0.07, reflecting a growth of 242.86%[4] - The diluted earnings per share also improved to ¥0.09 from a loss of ¥0.07, showing a 228.57% increase[5] - The weighted average return on equity rose to 1.03%, an increase of 1.73 percentage points compared to -0.70% in the previous year[5] - The net profit for Q1 2025 was CNY 15,380,038.91, a significant recovery from a net loss of CNY 11,649,422.29 in Q1 2024, marking a turnaround in performance[22] - Operating profit for the period was CNY 16,335,392.15, compared to an operating loss of CNY 16,307,021.90 in the same quarter last year[21] - The total comprehensive income for the period was CNY 15,380,038.91, contrasting with a total comprehensive loss of CNY -25,147,778.06 in the same quarter last year[22] Cash Flow and Operating Activities - The net cash flow from operating activities was negative at -¥78,629,355.18, worsening from -¥66,219,658.39 year-on-year, a decline of 18.74%[4] - The company reported a net cash outflow from operating activities of CNY -78,629,355.18, worsening from CNY -66,219,658.39 in Q1 2024[25] - Investment activities generated a net cash inflow of CNY 21,093,038.64, a decrease from CNY 72,663,039.38 in the previous year[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,780,508,415.67, a slight increase of 1.28% from ¥2,745,232,212.30 at the end of the previous year[5] - Current assets totaled RMB 1,596,224,573.62 as of March 31, 2025, compared to RMB 1,544,491,817.38 at the end of 2024, showing an increase of 3.3%[15] - Total liabilities were RMB 1,193,364,399.68 as of March 31, 2025, compared to RMB 1,174,190,825.27 at the end of 2024, indicating an increase of 1.6%[16] - Shareholders' equity totaled RMB 1,587,144,015.99 as of March 31, 2025, compared to RMB 1,571,041,387.03 at the end of 2024, representing a growth of 1.0%[17] Operating Costs and Expenses - Total operating costs for Q1 2025 were RMB 304,631,137.53, up from RMB 273,291,745.76 in Q1 2024, reflecting a growth of 11.5%[20] - Operating costs included RMB 273,689,998.82 in operating expenses for Q1 2025, compared to RMB 243,706,743.19 in Q1 2024, indicating a rise of 12.3%[20] - The company incurred research and development expenses of CNY 10,192,622.79, an increase from CNY 9,253,218.37 in the previous year, reflecting a focus on innovation[21] - Financial expenses included interest expenses of CNY 1,955,606.08, slightly up from CNY 1,872,472.48 in Q1 2024[21] Inventory and Cash Management - Cash and cash equivalents were RMB 557,380,441.70 as of March 31, 2025, down from RMB 575,009,309.85 at the end of 2024, a decrease of 3.0%[14] - Inventory increased to RMB 243,128,515.76 as of March 31, 2025, compared to RMB 231,412,437.26 at the end of 2024, marking a rise of 5.0%[15] - Cash and cash equivalents at the end of Q1 2025 stood at CNY 482,465,747.03, down from CNY 701,706,964.69 at the end of Q1 2024[26] Non-recurring Gains and Losses - Non-recurring gains and losses amounted to ¥1,807,181.73 after tax, with significant contributions from government subsidies and other income[7] - The company reported a significant increase in sales volume and price for key products, driving the growth in net profit and earnings per share[9]

Financial Performance - The net profit attributable to shareholders of Jiangsu Fengshan Group Co., Ltd. for the year 2024 was -38,625,401.12 RMB, showing a slight improvement of 1.36% compared to -39,159,426.56 RMB in 2023[6]. - The total operating revenue for 2024 was 1,043,719,124.23 RMB, a decrease of 12.76% from 1,196,373,565.89 RMB in 2023[24]. - The net cash flow from operating activities increased significantly by 123.37% to 155,838,907.40 RMB compared to 69,767,520.07 RMB in 2023[25]. - The total assets of the company as of the end of 2024 were 2,745,232,212.30 RMB, reflecting a 2.00% increase from 2,691,417,463.41 RMB at the end of 2023[25]. - The net assets attributable to shareholders of the company increased by 1.03% to 1,574,297,599.36 RMB compared to 1,558,235,015.21 RMB in 2023[25]. - Basic earnings per share for 2024 is -0.23 yuan, a 2.17% improvement compared to -0.24 yuan in 2023[26]. - The company reported a net cash flow from operating activities of 168,451,141.42 yuan in Q4 2024, indicating a significant recovery[28]. - Non-recurring gains and losses for 2024 totaled -2,851,502.91 yuan, with government subsidies contributing 5,093,451.83 yuan[29]. - Operating profit was reported at CNY -34,185,100, an improvement of 17.19% from the previous year's loss of CNY -41,279,400[63]. - The company's main business revenue decreased by 12.96% to CNY 1,039,093,000, primarily due to a downturn in the pesticide industry and significant price declines[65]. Shareholder Returns - The company will not distribute profits or conduct capital reserve transfers for the year 2024 due to the negative net profit[6]. - The company has outlined a three-year shareholder return plan for 2024-2026, which includes conditions for cash dividends based on positive distributable profits[6]. - The profit distribution plan for 2024 is to not distribute profits or increase capital reserves, which has been approved by the board[198]. - Due to the negative net profit, the company does not meet the conditions for cash dividends in 2024[198]. - The cash dividend policy complies with the company's articles of association and shareholder resolutions[199]. Risk Management - The company has provided a detailed risk statement regarding potential future risks in its management discussion and analysis section[9]. - The company recognizes risks related to environmental regulations and will continue to prioritize safety and environmental management to ensure stable operations[155]. - The company faces risks from raw material supply and price fluctuations, which could impact production and operational efficiency, and plans to enhance procurement strategies[156]. - The company will strengthen its international trade strategies to mitigate risks associated with export policies and currency fluctuations[159]. - The company faces risks related to fundraising projects not meeting expectations due to potential price increases in basic chemical products, which are the main raw materials for these projects[160]. Market and Product Development - The company is focusing on product quality and brand strength in the pesticide sector, emphasizing technological innovation and new product development[34]. - The company is advancing the development of new battery electrolyte products, including fast-charging and semi-solid battery electrolytes, to meet the needs of major clients in the industry[41]. - The company plans to enhance market development capabilities through technological innovation and collaborative research[35]. - The agricultural pesticide sector is experiencing a recovery in market demand since 2024, despite being in a price consolidation phase[47]. - The company is focusing on integrated development in the pesticide sector, enhancing its competitive advantage through a comprehensive approach to raw materials and formulations[134]. Corporate Governance - The company has established a governance structure that includes a board of directors, supervisory board, and senior management, ensuring clear responsibilities and regulatory compliance[165]. - The board consists of 8 members, including 3 independent directors, and operates through specialized committees to provide scientific and professional advice[166]. - The company has implemented measures to enhance investor relations and communication, including hosting quarterly online performance briefings[167]. - The company adheres to strict information disclosure regulations, with the chairman and board secretary responsible for ensuring transparency[167]. - The company has not identified any significant discrepancies between its governance practices and regulatory requirements[168]. Research and Development - The company has established several R&D platforms, including the Jiangsu Provincial Enterprise Technology Center and the Jiangsu (Fengshan) Chiral Pesticide Engineering Technology Center, to enhance its innovation capabilities[61]. - The company has received recognition as a high-tech enterprise as of 2024, with a total of 25 authorized invention patents and 2 utility model patents[61]. - The company has a strong focus on expanding its market presence through strategic partnerships and collaborations[177]. - The company is actively involved in research and development of new products and technologies to enhance its competitive edge[177]. - The company emphasizes the importance of sustainability and environmental responsibility in its business practices[177]. Operational Efficiency - The company aims to enhance operational efficiency and reduce costs by optimizing organizational structure and management levels, focusing on lean management across all value chains[39]. - The overall cost structure improved, with a significant reduction in environmental disposal fees and steam prices contributing to lower total costs[73]. - The company has implemented a performance evaluation system that emphasizes actual work efficiency and resource optimization to enhance productivity[39]. - The company plans to focus on pesticide products in 2024, with subsidiaries involved in electronic products and agricultural production[68]. - The company is committed to developing a full industrial chain of high-end fine chemicals, particularly focusing on toluene chlorination and fluorination, while exploring mergers and acquisitions to enhance market competitiveness[148].

江苏丰山集团股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条 为规范公司董事会审议委员会（以下简称"审计委员会"）的议事 程序，公司董事会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《 上市公司治理准则》《上市公司独立董事管理办法》《上海证券交易所股票上市 规则》等有关法律法规和规范性文件及《江苏丰山集团股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，制定本工作细则。 第二条 审计委员会是董事会下设的专门委员会，对董事会负责。审计委员 会主要负责审核公司财务信息及其披露、监督及评估内外部审计工作和内部控 制。 第二章 人员组成 第三条 审计委员会由三名不在公司担任高级管理人员的董事组成，其中独 立董事过半数且至少有一名独立董事为会计专业人士。由独立董事中会计专业 人士担任召集人。 前款所称会计专业人士应具备较丰富的会计专业知识和经验，并至少符合 下列条件之一： （一）具有注册会计师执业资格； （二）具有会计、审计或者财务管理专业的高级职称、副教授职称或者博 士学位； （三）具有经济管理方面高级职称，且在会计、审计或者财务管理等专业 岗位有5年以上全职工作经验。 第四条 审计 ...

江苏丰山集团股份有限公司 2024 年度独立董事述职报告 作为江苏丰山集团股份有限公司（以下简称"公司"）的独立董事，2024 年 度任职期间，本人积极参加交易所组织的学习培训，努力提高独立董事的履职水 平，严格按照《公司法》《上海证券交易所股票上市规则》《上海证券交易所上 市公司自律监管指引第 1 号—规范运作》《上市公司独立董事管理办法》等相关 法律法规的要求，勤勉尽责地履行独立董事的职责与义务，审慎行使公司和股东 所赋予的权利，积极出席董事会或股东大会等相关会议，认真审议董事会各项议 案，对重大事项发表了公正、客观的独立意见，充分发挥了独立董事的作用。不 受公司大股东、实际控制人或者其他与公司存在利害关系的单位或个人的影响， 维护了公司整体利益及中小股东的合法权益。现将 2024 年度履行职责情况汇报 如下： 一、独立董事的基本情况 本人经公司于 2024 年 5 月 20 日召开的 2024 年年度股东大会选举，担任公 司第四届董事会独立董事。2024 年度任职期间，作为独立董事，本人拥有专业 资质及能力，在从事的专业领域积累了丰富的经验，对公司董事会审议的议案， 从客观、公正的立场出发，做出独立判断 ...